GSK did not admit wrongdoing as part of the deal, saying in a statement that there was "no consistent or reliable evidence" that ranitidine, the drug's active ingredient, increased the risk of cancer.

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

Numerous drugs have been recalled in recent years over nitrosamine impurities, including metformin, ranitidine (Zantac), and ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

Heritage Pharmaceuticals and Apotex will pay $49.1 million in a settlement with Pennsylvania, New Jersey and other states.

MEGAN McKenna has opened up about the challenges of motherhood after her newborn son, Landon, received a painful medical diagnosis. The former Towie star revealed the toll it has taken on her ...

GSK targets £38 billion in sales by 2031, but market estimates fall short at £35.7 billion These cases account for 93% of the Zantac (ranitidine) lawsuits currently pending against the company.

Tens of thousands of Americans are in line to share $2.2bn (£1.7bn) after GSK agreed a settlement over claims its indigestion drug caused cancers. The British drug giant has agreed to pay up to $2.2bn ...

GSK did not admit wrongdoing as part of the deal, saying in a statement that there was "no consistent or reliable evidence" ...